Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Neuropathology associated with SARS-CoV-2 infection

We read with interest the Correspondence by Claus Hann von Weyhern and colleagues,[1] in which they report pronounced CNS involvement with pan-encephalitis in six patients with COVID-19 who were on invasive ventilation, some of whom were also receiving extracorporeal membrane oxygenation. Of these, three patients were further reported to have "massive intracranial" and "diffuse petechial haemorrhage in the entire brain".[1] These changes are then attributed directly or indirectly to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Having neuropathologically assessed brains of more than 41 patients with COVID-19, and having investigated the neurotropism of SARS-CoV-2, we do not concur with the conclusion that pan-encephalitis and CNS haemorrhage are common complications of COVID-19.[2,3] We do not observe pan-encephalitis, nor do we see massive intracranial haemorrhage or excessive and diffuse petechial haemorrhage in any of the brains of patients with COVID-19 that we have investigated (appendix).

See Online for appendix

It is well known that long-term intensive care involving invasive ventilation, and especially extracorporeal membrane oxygenation, can lead to intracranial haemorrhagic lesions and diffuse neuroimmune activation.[4] Additionally, immune activation should not be confused with encephalitis, and petechial haemorrhage routinely observed in brains of critically ill patients should not be over-interpreted as CNS haemorrhage. Moreover, other neuropathological studies of COVID-19 brains have not found any evidence of encephalitis or intracranial haemorrhage.[5]

Neuropathological assessment of patients with COVID-19, especially those dying under intensive care treatment, is an expert task and all observed changes must be carefully interpreted in the context of comorbidities and therapeutic interventions to avoid misinterpretation.

MG reports grants from the German Federal Ministry of Education and Research (Defeat Pandemics) and by the state of Hamburg with Landesforschungsförderung. AT received funding from the Botnar Research Centre for Child Health. All other authors declare no competing interests.

*Markus Glatzel, Christian Hagel, Jakob Matschke, Jan Sperhake, Nikolaus Deigendesch, Alexandar Tzankov, Stephan Frank
m.glatzel@uke.de

Institute of Neuropathology (MG, CH, JM) and Institute of Legal Medicine (JS), University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany; Institute of Pathology, Basel University Hospitals, Basel, Switzerland (ND, AT, SF)

1 von Weyhern CH, Kaufmann I, Neff F, Kremer M. Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. *Lancet* 2020; **395:** e109.
2 Puelles VG, Lütgehetmann M, Lindenmeyer MT, et al. Multiorgan and renal tropism of SARS-CoV-2. *N Engl J Med* 2020; **383:** 590–92.
3 Matschke J, Lütgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. *Lancet Neurol* 2020; **19:** 919–29.
4 Le Guennec L, Cholet C, Huang F, et al. Ischemic and hemorrhagic brain injury during venoarterial-extracorporeal membrane oxygenation. *Ann Intensive Care* 2018; **8:** 129.
5 Schaller T, Hirschbühl K, Burkhardt K, et al. Postmortem examination of patients with COVID-19. *JAMA* 2020; **323:** 2518–20.

We believe that many of the key findings described in the Correspondence by Claus Hann von Weyhern and colleagues[1] should be interpreted differently. The exact nature of CNS involvement in COVID-19 is not only of fundamental importance for our understanding of the disease, but might have substantial consequences in directing clinical efforts to achieve better patient management in the future. Thus, observations about CNS inflammation as described by von Weyhern and colleagues will cause a great stir among biomedical scientists and clinicians if proven to be correct. However, we feel obliged to express our sincere reservations about the conclusions drawn from these data given the potentially wide-ranging consequences.

We particularly feel that the main conclusion, namely that "in addition to viral pneumonia, a pronounced CNS involvement with pan-encephalitis, meningitis, and brainstem neuronal cell damage were key events",[1] are possibly the consequence of a misinterpretation of histological findings. Although it is conceivable that hypoxic-ischaemic neuronal damage could occur as part of COVID-19, the depicted neuronal changes characterised by contracted, intensely stained neurons do not represent hypoxic, but rather suggest dark neurons.[2] Dark neurons are frequent histological artifacts usually caused by post-mortem manipulation of the brain before fixation, and differ from dying or degenerating neurons.

Furthermore, we find the data illustrating the inflammatory involvement of the CNS in patients with COVID-19 unconvincing. Although we agree that a possible direct or indirect CNS involvement in the context of severe acute respiratory syndrome coronavirus 2 infection merits investigation, we cannot support the diagnosis made by the authors of pan-encephalitis or meningitis on the basis of the provided data and histological photomicrographs provided. We acknowledge the modest perivascular T-cell population depicted by immunohistochemistry by CD3 staining. However, such minimal lymphocytic CNS infiltrates are quite commonly seen in patients with multisystem failure (who required treatment in the intensive care unit), and we feel that these are non-specific changes whose clinical relevance is debatable. In our opinion, the histological findings have been over-interpreted as pan-encephalitis or meningitis. We would also highlight Solomon and colleagues' findings,[3] which are in line with our assessment (and also our observations of CNS COVID-19 autopsies performed at our centres), namely that encephalitis is not a general feature of COVID-19.